Allogene Therapeutics Inc ALLO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
-
Allogene Therapeutics Announces Participation in September Investor Conference
-
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
-
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
-
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Trading Information
- Previous Close Price
- $1.33
- Day Range
- $1.31–1.37
- 52-Week Range
- $1.04–4.46
- Bid/Ask
- $1.31 / $1.37
- Shares Outstanding
- 345.49M
- Market Cap
- $459.50M
- Volume/Avg
- 5M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 72.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 152
- Website
- https://www.allogene.com
Valuation
|
Metric
|
ALLO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.05 |
Price/Sales | 72.94 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALLO
|
|---|---|
Quick Ratio | 10.48 |
Current Ratio | 10.72 |
Interest Coverage | −138.46 |
Quick Ratio
ALLO
Profitability
|
Metric
|
ALLO
|
|---|---|
Return on Assets (Normalized) | −28.17% |
Return on Equity (Normalized) | −38.38% |
Return on Invested Capital (Normalized) | −34.76% |
Return on Assets
ALLO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|LhLX!&M | LOCK|w!#Yq | $133B | |||
| Moderna Inc
MRNA
| LOCK|Pyp!G$l | LOCK|VB | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%&F!wN | LOCK|hFmd$ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|f?VS@t | LOCK|># | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|fKX>d&^ | LOCK|bDR | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|b<l>$#< | LOCK|rcfb& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>gm%^B@% | LOCK|$Ft% | $28B | |||
| Incyte Corp
INCY
| LOCK|@cT#PS! | LOCK|Cy@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#W%%%W! | LOCK|?!h | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|nf%ySL% | LOCK|^m | $14B |
United States